GLUE biotech catalysts & pipeline

MONTE ROSA THERAPEUTICS INC · Data as of 2026-09-08

Upcoming catalysts

CDK2 and/or cyclin E1-directed MGD — IND submission

2026

The Company remains on track to submit an IND application in 2026 for a CDK2 and/or cyclin E1-directed MGD.

Source filing

cyclin E1-directed MGD — IND submission

H2 2026

Monte Rosa expects to submit an IND application for its CCNE1 MGD program in H2 2026.

Source filing

MRT-55811 — IND submission

H2 2026

Preclinical data presented at AACR highlight a novel cyclin E1-directed MGD with superior selectivity and reduced off-target activity compared to CDK2 inhibitors; IND submission anticipated in H2 2026

Source filing

MRT-8102 — Topline data

H2 2026

Completed enrollment and dosing for GFORCE-1 study of MRT-8102 in subjects with elevated cardiovascular disease (CVD) risk; readout anticipated in H2 2026

Source filing

NEK7-directed MGD — IND submission

H2 2026

Submit an IND application for a second-generation NEK7-directed MGD in H2 2026.

Source filing

second-generation NEK7-directed MGD — IND submission

H2 2026

Submit an IND application for a second-generation NEK7-directed MGD in H2 2026.

Source filing

MRT-2359 — Topline data

Late 2026

Update on the initial Phase 1/2 expansion arm exploring MRT-2359 in combination with enzalutamide in advanced CRPC by the end of the year.

Source filing

cyclin E1-directed MGD — IND submission

2027

Submit an IND application for a cyclin E1-directed MGD in 2027.

Source filing

Explore the free biotech catalyst calendar